Takeda Pharmaceutical Company Limited (TAK)
| Previous Close | 14.24 |
| Open | 14.16 |
| Bid | 14.16 x 800 |
| Ask | 14.30 x 4000 |
| Day's Range | 14.12 - 14.20 |
| 52 Week Range | 13.05 - 17.31 |
| Volume | |
| Avg. Volume | 2,594,048 |
| Market Cap | 44.142B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | 10.88 |
| EPS (TTM) | 1.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.80 (5.50%) |
| Ex-Dividend Date | Sept 29, 2021 |
| 1y Target Est | 19.13 |
- GlobeNewswire
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce
- Zacks
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
